DR. PETRY genmedics GMBH

Resources and expertise in applied gene technology, specialised in Staphylococcus research

DR. PETRY genmedics is a privately held biotech company founded in 1998 as a spin-off from the Department of Microbial Genetics of the University of Tübingen. In 2004 the company received financial support through the BioChance PLUS programme of the Federal Ministry for Education and Research (BMBF).

Justus Dehnen, CEO
Jörg Petry, Dr., CFO
Bernhard Krismer, Dr., CSO
Günther Thumm, Dr., COO

Friedrich Götz, Prof. Dr.
Günther Jung, Prof. Dr.
Joachim-Volker Höltje, Prof. Dr.
Rolf G. Werner, Prof. Dr. Dr.h.c.

Ferdinand-Lassalle-Strasse 57
72770 Reutlingen
Germany
Phone: +49-7121-9589-0
Fax: +49-7121-9589-33

The company focuses on applied gene technology including the development and manufacturing of anti-infectives for life science companies and veterinary medicines, expression and purification of plasmid DNA, recombinant DNA derived peptids and proteins for industrial and therapeutic applications, custom-made research tools, bioactivity assay development and high throughput screening, detection and quantification of targets for biofilm formation on medical and industrial materials, detection and quantification of pathogenicity factors and resistance markers of staphylococci, optimisation of host strains and food-grade staphylococcal strains and the production of heterologuous proteins and industrial enzymes using the food-grade Staphylococcus carnosus. A major focus of the company is the search for and the development and production of new anti-infectives against multiply resistant Gram-positive bacteria (Methicillin- or Vancomycin-resistant Staphylococcus aureus, Vancomycin-resistant enterococci and clostridia. To detect further anti-infective lead substances, potential drug targets are identified in pathogenic bacteria and promising drug candidates are screened. A project funded by “BioProfile Regenerative Biology”, carried out in cooperation with SOURCON PADENA, Tübingen, deals with the development of new substances against biofilm formation (especially by Staphylococcus epidermis) on regenerative and synthetic tissue implants.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.